Navigation Links
Perrigo Announces FDA Approval for Generic Version of NASACORT(R) AQ
Date:8/3/2009

ALLEGAN, Mich., Aug. 3 /PRNewswire-FirstCall/ -- Perrigo Company (Nasdaq: PRGO; TASE) today announced that its partner Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) (previously Barr Laboratories Inc.) has received final approval from the U.S. Food and Drug Administration to market Triamcinolone Acetonide Nasal Spray containing a paragraph IV certification. Perrigo's partner Teva was the first applicant to file a complete ANDA with a Paragraph IV certification for NASACORT AQ. The product was developed at Perrigo.

Under the terms of a previously disclosed settlement, Teva will be able to market the ANDA product which is manufactured by Perrigo under license from Sanofi-Aventis commencing on June 15, 2011. Perrigo will share in the costs and benefits in Teva's marketing of the products under the agreement.

The product is the AB-rated equivalent to Sanofi - Aventis' Nasacort(R) AQ, indicated for the treatment of the nasal symptoms of seasonal and year round allergies in adults and children six years of age and older. Sales for the brand were approximately $305 million, according to Wolters Kluwer data for the twelve months ending June 2009.

Perrigo's Chairman and CEO Joseph C. Papa concluded, "This approval is a terrific example of Perrigo's strategic focus on developing challenging products in the extended topical categories. It further demonstrates our strategy to deliver quality affordable healthcare for generic prescriptions and over the counter products."

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes OTC and generic prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients (API) and consumer products. The Company is the world's largest manufacturer of OTC pharmaceutical products for the store brand market. The Company's primary markets and locations of manufacturing and logistics operations are the United States, Israel, Mexico and the United Kingdom. Visit Perrigo on the Internet (http://www.perrigo.com).

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 28, 2008, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Perrigo Company
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Perrigo Receives FDA Approval to Market Cherry and Cinnamon Flavored Nicotine Lozenges
2. Perrigo Confirms That its Partner Synthon Has Filed for Generic Version of Xyzal(R) Solution and Announcement of Lawsuit by Sepracor/UCB
3. Perrigo Reports Record Third Quarter
4. Perrigo Company Announces Quarterly Dividend
5. Perrigo Announces FDA Approval for Sulfacetamide Sodium Topical Suspension USP, 10% (Lotion)
6. Perrigo Begins Shipments of Ibuprofen PM
7. Perrigo Reports Record Second Quarter Sales
8. Perrigo Company Announces Quarterly Dividend
9. Perrigo Company Appointed Generic Distributor by Medimetriks Pharmaceuticals
10. Perrigo Company Will Release Second Quarter Fiscal Year 2009 Results on February 3, 2009
11. Perrigo Company to Present at the 27th Annual JPMorgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... ... Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The ... published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the placement ... Vice President of North American Capital Sales at HTG Molecular . ... in the commercialization of the HTG EdgeSeq system and associated reagents in North America. ...
(Date:6/24/2016)... ... 2016 , ... Finally, a bruise cream that really works. Originally designed ... into the post-surgical treatment plans of a variety of other procedures including, but not ... effective for bruising and causes a rapid resolution of bruising and inflammatory changes compared ...
(Date:6/24/2016)... ... June 24, 2016 , ... SpiritQuest Sedona Retreats, located in Arizona ... surrounded by famous vortex sites: Cathedral Rock, Airport Mesa, and Boynton Canyon. The new ... Lodge at Sedona as well as the Sedona Rouge, both popular accommodations for SpiritQuest ...
(Date:6/23/2016)... ... 2016 , ... vcfo, a consulting firm that provides access ... the promotion of Mike Mackey to Regional Vice President of Southeast Texas. , ... for managing client projects and overseeing vcfo financial consultants in the Houston area. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... ANDOVER, Mass. and SAN CLEMENTE, Calif. ... California -based mobile pulmonary function testing company, is now ... portable PFT devices developed by ndd Medical Technologies , Inc. ... PFT testing done in hospital-based labs.  Thanks to ndd,s EasyOne PRO ... CA , can get any needed testing done in the ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
(Date:6/23/2016)... Ill. , June 23, 2016  In a startling report ... are failing their residents by lacking a comprehensive, proven plan to ... a definitive ranking of how states are tackling the worst ... to only four states – Kentucky , ... Vermont . Of the 28 failing states, three ...
Breaking Medicine Technology: